COVID-19 Treatment To Be Tested At Regional Biocontainment Lab

Innovation Pharmaceuticals Brilacidin antiviral and anti-inflammatory properties will be tested in the context of viral infections
graphic with the world and covid-19 across the world

A Massachusetts based biopharmaceutical company announced the signing of a Material Transfer Agreement (MTA) with a Regional Biocontainment Labs (RBLs) to research its defensin mimetic drug candidate, Brilacidin, as a potential novel coronavirus 2019 (COVID-19) treatment. 

Now that the MTA has been signed, the first shipments of Brilacidin will be made to the RBL in the coming days, said the company’s February 27, 2020, press release.

Under terms of the agreement with Innovation Pharmaceuticals, scientific researchers at the RBL will evaluate Brilacidin’s potential antiviral and anti-inflammatory properties in the context of viral infections, including inhibition of SARS-CoV-2, the coronavirus responsible for COVID-19 disease.

Mechanism of action studies of Brilacidin, along with assessing possible synergistic effects with other antivirals, are also planned. 

It is anticipated by Innovation that these tests might be completed within several weeks of the RBL’s receipt of Brilacidin.

This is potentially good news since the US Food and Drug Administration (FDA) has not approved any medication as of February 27th to treat patients suffering from COVID-19.

As previously disclosed, Innovation Pharmaceuticals has been receiving inquiries about the potential to use a defensin mimetic to meet an urgent global need to treat COVID-19.

Brilacidin is one of several medications currently under evaluation to treat this new disease.

The Company also has successfully completed a Phase 2 trial of Brilacidin in Oral Mucositis, aligning with the FDA on a planned Phase 3 program.

Innovation Pharmaceuticals said ‘it continues to explore additional research collaborations with leading U.S. and Asian-based virology laboratories, global public health coalitions, and rapid-response government-backed efforts.’

Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly-traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies.

Novel coronavirus 2019 treatment development news published by Precision Vaccinations.